AstraZeneca to develop cardiovascular disease treatments with university
WILMINGTON, Del. AstraZeneca has inked a collaboration with the University of Virginia in Charlottesville, Va., to develop treatments for cardiovascular disease, the Anglo-Swedish drug maker announced Tuesday.
The two will develop new treatments for coronary artery disease, with a secondary focus on peripheral vascular disease, identifying disease mechanisms and biological targets as starting points for creating new medicines. Financial terms were not disclosed.
“This is an area of high unmet medical need: Atherosclerosis is a primary cause of cardiovascular morbidity and mortality,” AstraZeneca VP cardiovascular and gastrointestinal research Bjorn Wallmark said. “AstraZeneca is committed to finding innovative solutions. By partnering with the University of Virginia and working together on the complex biology of these diseases, it increases the potential of delivering new treatment options.”
Walgreens expands H1N1 flu shots to more than 100 Florida pharmacies
DEERFIELD, Ill. Accelerating its rollout of a large-scale immunization effort, Walgreens said Monday it has begun offering both H1N1 injectable and nasal vaccines at more than 100 pharmacies in Florida.
Those stores are located in Orange, Seminole, Osceola, Sumter and Marion counties. Take Care Clinics at Walgreens stores in the Orlando area also are now offering H1N1 vaccinations to patients ages 2 years and older.
The move comes just days after the 7,147-store drug chain rolled its flu shot program into Louisiana, and it brings to 31 the number of states where Walgreens now offers immunizations for the virus. Walgreens said it would offer H1N1 vaccinations “in additional counties throughout central Florida in the coming weeks as supply becomes available.
“Walgreens and Take Care Health Systems are working closely with public health officials to serve as a state-wide distribution partner for the H1N1 vaccine and a community resource for information on H1N1 immunization,” announced company spokesman Jim Cohn.
While supplies last, the chain is offering vaccinations on a walk-in basis whenever an immunizing pharmacist is on-staff, for a fee of $18. Shots are also available during scheduled H1N1 clinics. Walgreens pharmacists in Florida can immunize those ages 18 years and older, and nurses attending select clinics at Walgreens stores can provide H1N1 immunizations to patients as young as two years old.
Local health departments throughout central Florida recently broadened recommendations on who should get an H1N1 vaccination to include everyone over the age of six months. With priority group restrictions eased, the chain is making the vaccine available to all residents who meet state age requirements in its participating Walgreens stores in Florida.
“We’re proud to partner with public health officials in central Florida to provide convenient, affordable access to H1N1 vaccinations,” said Marlin Hutchens, Walgreens Florida market VP.
Bancroft steps in as Bristol-Myers Squibb’s acting CFO
NEW YORK The former VP finance for Bristol-Myers Squibb Co.’s global biopharmaceutical business has been appointed as the company’s acting CFO, Bristol announced Monday.
Charles Bancroft will assume the position on Jan. 1 and continue to report to president and COO Lamberto Andreotti, following the planned departure of CFO and EVP Jean-Marc Huet at the end of this year.
“Jean-Marc has indicated to me his desire to return to Europe, and we wish him every success,” Bristol chairman and CEO James Cornelius said in a statement. “The board of directors and I are grateful to Jean-Marc for his strategic work in rapidly and successfully solidifying our balance sheet, his focus on increasing our cash position to nearly $10 billion through a series of important transactions and his leadership of continuous improvement initiatives, which have greatly accelerated our biopharma transformation.”
Bancroft began working for Bristol in 1984 and has served in various finance positions with the company, including in other countries.
“Charlie has a wide range of technical and operational finance experiences, including strong financial stewardship, business partnering and leadership capabilities which will serve him well in his new role,” Cornelius said. “We have a strong finance team who will maintain our focus on delivering shareholder value.”